This protocol addresses patients with advanced or metastatic non-small cell lung cancer (NSCLC) in whom an NRG1 gene fusion has been identified. NRG1 gene fusions are rare, estimated to occur in less than 1% of patients diagnosed with NSCLC, and they define a distinct molecular subtype with specific therapeutic implications.
Confirmed NRG1 gene fusion is the key molecular criterion for this patient population. The presence of this fusion is associated with responsiveness to a HER2/HER3 bispecific antibody, making molecular testing essential before treatment decisions are made.
For patients with NRG1 gene fusion-positive advanced or metastatic NSCLC whose disease has progressed, a targeted bispecific antibody-based agent is included as a subsequent therapy option. The complete regimen details, eligibility criteria, and management algorithm are contained in the full structured protocol.